GeneDx Holdings Corp. Class A Common Stock
WGSStock
$61.69−24.23%52W
Market Cap$1.87B
P/E—
Div yield—
Beta2.00
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-62.70%
Price vs S&P 500 (4W)2.21%
VGM Score39.52
Market Capitalization$1.87B
Earnings Surprise History
Q1 26-0.28est. -0.01
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.23
4.23
4.23
4.23
Industry Peers — Health Services(21)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
WGSGeneDx Holdings Corp. Class A Common Stock | F | B | D | $61.69 |
| LFSTLifeStance Health Group, Inc. Common Stock | D | B | A | $11.29 |
| PRVAPrivia Health Group, Inc. Common Stock | D | B | B | $27.22 |
| INNVInnovAge Holding Corp. Common Stock | D | C | A | $11.87 |
| OMDAOmada Health, Inc. Common Stock | F | A | B | $23.67 |
| PNTGThe Pennant Group, Inc. Common Stock | D | B | B | $41.71 |
| USPHUS Physical Therapy Inc | C | C | D | $74.19 |
| TALKTalkspace, Inc. Common Stock | F | B | C | $5.22 |
| SRTAStrata Critical Medical, Inc. Class A Common Stock | B | A | B | $5.23 |
| ALPSALPS Group Inc Ordinary Share | — | — | F | $0.45 |
| PIIIP3 Health Partners Inc. Common Stock | A | C | A | $11.11 |
About
GeneDx Holdings develops exome and genome sequencing technologies for diagnosing rare and ultra-rare pediatric genetic disorders. The company addresses a growing market opportunity as genetic testing becomes the standard diagnostic approach, enabling earlier diagnoses and improved patient outcomes. With a core business in pediatric and rare disease diagnostics, GeneDx is expanding into data and information services as precision medicine adoption accelerates.